Apricus signs Vitaros licensing deal, shares gain

Apricus' (APRI) shares gain 8% after the company signs an exclusive licensing agreement with Italy's Recordati (RCDTF) to market Apricus' Vitaros cream for erectile dysfunction in Spain, Russia, Turkey, Ireland and other European countries, and in some African markets.

Apricus will receive $3.8M up front, as much as $47M in sales milestone payments and royalties. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs